Search

Your search keyword '"Huckriede, Anke L.W."' showing total 23 results
Start Over Author "Huckriede, Anke L.W."
23 results on '"Huckriede, Anke L.W."'

4. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Author

Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

7. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

Author

Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., and GeurtsvanKessel, Corine H.

Abstract

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.

Published
2023

8. Een vooruitblik op covid-19-vaccinatie en -behandeling

Author

de Boer, Mark G.J., Bonten, Marc J.M., Huckriede, Anke L.W., Transplantation Immunology Groningen, and Microbes in Health and Disease

Abstract

Vaccination or recent exposure to infection with SARS-CoV-2 currently grants the vast majority of the population considerable immunity and thereby protection against severe disease. It is yet unknow how long this protection lasts. Continuous changes of the viral genotype and phenotype herein play an important role, in particular the variant-specific alterations of the spike protein. Protection by T-cell immunity seems to be more preserved in the event of changes in the virus as compared to antibody-mediated host defences. Furthermore, the continuous succession of virus variants also directly and indirectly affects the effectiveness of medical treatment. Regarding immune-modulating as well as anti-viral therapy, the viral characteristics of the circulating SARS-CoV-2 variant in combination with the level of host immunity will determine whether their use makes sense, and for which patients. The number of patients needed to treat to prevent a clinically negative outcome herein represents an important figure.

Published
2022

9. COVID-19 vaccination: the VOICE for patients with cancer

Author

van der Veldt, Astrid A. M., Oosting, Sjoukje F., Dingemans, Anne-Marie C., Fehrmann, Rudolf S. N., GeurtsvanKessel, Corine, Jalving, Mathilde, Rimmelzwaan, Guus F., Kvistborg, Pia, Blank, Christian U., Smit, Egbert F., Lemmens, Valery E.E.P., Hiltermann, Jeroen N., Koopmans, Marion P.G., Huckriede, Anke L.W., Rots, Nynke Y., van Els, Cecile A.C.M., van Baarle, Debbie, Haanen, John B.A.G., and de Vries, Elisabeth G.E.

Subjects
Cancer patients -- Drug therapy, Biological sciences, Health
Abstract

Author(s): Astrid A. M. van der Veldt [sup.1] , Sjoukje F. Oosting [sup.2] , Anne-Marie C. Dingemans [sup.3] , Rudolf S. N. Fehrmann [sup.2] , Corine GeurtsvanKessel [sup.4] , Mathilde [...]

Published
2021
Full Text
View/download PDF

10. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers:The SWITCH ON trial protocol

Author

Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, van der Kuy, Hugo, Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, and van der Kuy, Hugo

Abstract

Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05471440.

Published
2022

11. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Author

Sablerolles, Roos S.G., primary, Rietdijk, Wim J.R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Geers, Daryl, additional, Schmitz, Katharina S., additional, Garcia Garrido, Hannah M., additional, Koopmans, Marion P.G., additional, Dalm, Virgil A.S.H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L.W., additional, Lafeber, Melvin, additional, van Baarle, Debbie, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, P. Hugo M., additional

Published
2022
Full Text
View/download PDF

15. Het grote inenten is begonnen

Author

Huckriede, Anke L.W., Transplantation Immunology Groningen, and Microbes in Health and Disease

Published
2021

16. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens:The SWITCH Trial Protocol

Author

Sablerolles, Roos S.G., Goorhuis, Abraham, GeurtsvanKessel, Corine H., de Vries, Rory D., Huckriede, Anke L.W., Koopmans, Marion P.G., Lafeber, Melvin, Postma, Douwe F., van Baarle, Debbie, Visser, Leo G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Rietdijk, Wim J.R., van der Kuy, P. Hugo M., Sablerolles, Roos S.G., Goorhuis, Abraham, GeurtsvanKessel, Corine H., de Vries, Rory D., Huckriede, Anke L.W., Koopmans, Marion P.G., Lafeber, Melvin, Postma, Douwe F., van Baarle, Debbie, Visser, Leo G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Rietdijk, Wim J.R., and van der Kuy, P. Hugo M.

Published
2021

17. Pulmonary Administration of Subunit Vaccines

Author

Tonnis, Wouter F., Huckriede, Anke L.W., Hinrichs, Wouter L.J., Frijlink, Henderik W., Foged, Camilla, Rades, Thomas, Perrie, Yvonne, Hook, Sarah, Pharmaceutical Technology and Biopharmacy, Microbes in Health and Disease (MHD), Translational Immunology Groningen (TRIGR), Nanotechnology and Biophysics in Medicine (NANOBIOMED), and Biopharmaceuticals, Discovery, Design and Delivery (BDDD)

Subjects
Immune system, business.industry, Immunology, Medicine, Subunit vaccines, subunit vaccine, Target population, business, Administration (government), Measle vaccine
Abstract

Pulmonary administration of vaccines might overcome some of the disadvantages related to administration by needle. The lungs are equipped with various immune cells through which a systemic as well as a mucosal immune response can be induced. Different types of devices and formulations can be used to administer vaccines to the lungs, each with their own advantages and disadvantages. The choice for a device and formulation is also dependent on the intended target population. A lot of research has been performed on pulmonary administration of vaccines, but safety data is lacking at the moment.

Published
2014
Full Text
View/download PDF

18. IgG antibody and TH1 immune responses to influenza vaccination negatively correlate with M-protein burden in monoclonal gammopathy of undetermined significance

Author

Tete, Sarah M, primary, Horst, Gerda, primary, Wilting, Kasper R, additional, Klijn, Michiel A, additional, Westra, Johanna, additional, de Haan, Aalzen, additional, Huckriede, Anke L.W, additional, Kluin-Nelemans, Hanneke C, additional, Sahota, Surinder S, additional, Bijl, Marc, additional, and Bos, Nico, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results